


Disclaimer

The information we provide may include references to a Genentech product or use of a Genentech product that the FDA has not approved; because the FDA has not approved such product(s) or use, no conclusions regarding safety or efficacy may be made.

FENhance 1 & 2 Phase III Studies in RMS



[†]12-week composite confirmed disability progression (cCDP12) is a composite outcome measure defined as the first occurrence of: a CDP-EDSS confirmed at 12 weeks OR a sustained increase of at least 20% from baseline in T25FWT score OR a sustained increase of at least 20% from baseline in 9-HPT score. CDP-EDSS is defined as a sustained increase of ≥1.0 points from baseline scores ≤5.5 (or ≥0.5 points from baseline EDSS scores ≥6.0).

BL, baseline; cCDP12, composite confirmed disability progression at 12 weeks; EDSS, Expanded Disability Status Scale; FEN, fenebrutinib; MRI, magnetic resonance imaging; OLE, open-label extension; Q12Wk, every 12 weeks; RMS, relapsing MS.

MS.Hauser S, et al. Presented at MSVirtual 2020 (P0211).

A Member of the Roche Group